Abstract: Considering that the majority of BD patients are from APLAR (Asia and Pacific League of Associations for Rheumatology) countries any diagnosis criteria for BD must have an adequate accuracy in these countries. The APLAR subcommittee for Behcet's Disease has set a prospective study to assess the accuracy of the existing diagnosis criteria. China, Iran, Japan, and Korea, the major countries with BD are participating to this study. The data from ...
Outcome analysis of ocular lesions in Behcet’s disease with six different therapeutic methods.
Abstract: Introduction: Ocular lesions are the major cause of morbidity in Behcet's Disease. If not treated, they usually progress toward severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic arsenal used for this condition. Materials & Methods: in an open, non randomized control study. Pulse Cyclophosphamida (PCP), low dose pulse cyclophosphamide (LDP), oral cyclophosphamide (OCP). weakly methotrexate (MTX), chlorambucil (CHL), and cyclosporine A (CYA) were used in a standard ...
Proposed ocular Behcet therapeutic scoring and activity/chronicity ratio.
Abstract: The aim of this study is to propose a scoring system to determine the activity of the eyes, and to evaluate our medications in the treatment of ocular inflammation and vasculitis in Behect's disease (BD). Eleven activity and 5 chronicity (constant) parameters are scored from zero to 4 to consider the condition of each eye in Oculo-Behcet's disease. Both parameters are considered in our therapeutic scoring. The activity variables are: Episcleritis and/or ...
Cyclosporine in severe Ocular Lesions of Behcet’s Disease.
Abstract: Introduction: There are several reports of good effects of Cyclosporine A (CsA) in the treatment of Behcet's disease (BD). We studied the long term effect of CsA in prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and/or RV diagnosed as BD (according to the Iran and to the Japan criteria) were selected. Initially CsA 5 mg/Kg/day orally ...
Cyclosporine in the treatment of severe ocular lesions of Behcet’s disease.
Abstract: Introduction: there are several reports of good effects of Cyclosporine A (Cs A) in the treatment of Behcet's disease (BD). We studied the long term effect, of A Cs A in a prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and / or RV diagnose as BD (according to the Iran and to the Japan criteria) ...
Proposed ocular Behcet therapeutic scoring & activity/chronicity ratio.
Abstract: Behcet’s Unite, Shariati Hospital the aim to propose a scoring system for the treatment of the ocular inflammation one vasculitis by our medications and to evaluate the state of the activity of the eye. Eleven activity and five chronicity (constant) parameters are scored from zero to four to consider the condition of each eye. The activity variables are: episcleritis &/or scleritis, anterior uveitis, hyalites, IMU, central periphlebitis &/or thrombosis, central periartertis, peripheral ...
Treatment of Ophthalmologic Manifestations Of Behcet’s Disease Comparison Of 6 Methods.
Abstract: Introduction: Opthalmologic manifestations are the major cause of morbidity in Behcet’s Disease. If not treated, they usually progress toward sever loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents. Materials & Methods: In an open, non randomized, control study, pulse cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), weakly methtrexate (MTX), chlorambucil (CHL), oral cyclophosphamide (OCP), and cyclosporine A (CYA) were used in a standard protocol for 778 patients. ...
Behcet’s Disease. Analysis of 2806 cases.
Abstract: There are only two nationwide surveys of Behcet's Disease (BD) in the world, one from Japan and one from Iran. The comparison of the two surveys is interesting because the populations are racially different, although they share same genetic background via the invasion of Iran by Turk tribes (from the northem part of China) in the 10 th and 13 th century. The annual incidence of BD in Iran is 350 ...
Evaluation and Risk Factors in the Ocular Behcet’s Disease.
Abstract: Porpose: To determine the risk factors in the prognosis and the visual outcome of the disease. Methods: This is a retrospective study of 361 patients, having Behcet’s disease and treated by immunosuppressives and steroids, followed-up at Shariatti Hospital (mean duration of follow-up was 2.27 years). The ocular examinations at the first and last visit are recorded and compared. Results: Vision ...
Long-Term Follow up of Type IV SLE Nephritis (without renal failure) Treated by Pulse Cyclophosphamide.
Abstract: Results of PCP are well known in lupus nephritis. We present here it’s outcome in patients with WHO type IV lupus nephritis, treated before the occurrence of renal failure. Patients having a follow up of more than 36 months were selected for this study. 29 patients fulfilled the selection criteria. Proteinuria, hematuria, leucocyturia, cast, BUN, creatinine and blood pressure were measured before PCP and after each one. The first and ...